Pharmacokinetics of glipizide in man: Influence of renal insufficiency

@article{Balant2005PharmacokineticsOG,
  title={Pharmacokinetics of glipizide in man: Influence of renal insufficiency},
  author={Luc P. Balant and Gaston R. Zahnd and A. Gorgia and Rudolf Schwarz and Jean Fabre},
  journal={Diabetologia},
  year={2005},
  volume={9},
  pages={331-338}
}
SummaryFour subjects received 5 mg14C-glipizide orally and3 subjects1 mg intravenously. The average absorption of the oral dose was nearly 100% with peak plasma levels occurring between 90 and 360 min. The apparent half-life of plasma radioactivity was approximatively 3.7 h, the disappearance of radioactivity following complex kinetics due to metabolism of the drug. Extraction with CH2Cl2 and chromatography showed that in plasma 85% of the total radioactivity corresponded to unchanged glipizide… 
Comparison of the pharmacokinetics of glipizide and glibenclamide in man
TLDR
The two sulfonylureas were extensively metabolized and were excreted in the urine as hydroxylated or conjugated metabolites and the effects of both drugs on blood glucose and immunoreactive insulin were comparable.
Radioimmunoassay of glipizide in human plasma
TLDR
A simple, sensitive radioimmunoassay has been developed for the direct determination of glipizide in human plasma and the results were in accordance with those found after administration of the same dose of radiolabelled glipIZide to two other subjects.
Bioavailability File: Glipizide
  • Medicine, Biology
TLDR
The physicochemical and pharmacological properties, determination methods and pharmacokinetics of Glipizide, a member of the second-generation sulfonylurea drugs used in the treatment of type 2 diabetes mellitus, are reviewed.
Glipizide: A Review of its Pharmacological Properties and Therapeutic Use
TLDR
Treatment with glipizide has resulted in satisfactory control of hyperglycaemia in a higher proportion of newly diagnosed patients not controlled on diet alone, than in patients previously treated with other sulphonylurea drugs, particularly when not well controlled on these drugs.
Bioavailability of Immediate- and Extended-Release Formulations of Glipizide in Healthy Male Volunteers
TLDR
The newly developed formulation (GLPF) maintained effective levels of glipizide for a period of more than 20 hours, with quicker onset of action than the other two formulations, and may be more economical than glipzide GITS.
Combination of glibenclamide–metformin HCl for the treatment of type 2 diabetes mellitus
TLDR
Combination of glibenclamide and metformin hydrochloride simultaneously addresses two different but complimentary mechanisms to improve glycemic control in type 2 diabetes and allows for reduced pill burden while treating a multifactorial disease by two different mechanisms.
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
  • A. Scheen
  • Medicine
    Expert opinion on drug metabolism & toxicology
  • 2013
TLDR
The author performed an extensive literature search to analyze the influence of RI on the pharmacokinetics (PK) of glucose-lowering agents and the potential consequences for clinical practice and found new antidiabetic agents are better tolerated in case of CKD, although clinical experience remains quite limited.
Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
TLDR
Conversion from glyburide to glipizide was associated with an increase in A1c, but the incidence of hypoglycemia was reduced, and results of this study are consistent with the recommendation of the American Diabetes Association and European Association for the Study of Diabetes to use second-generation sulfonylureas other than glyBuride.
Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties.
  • P. Arnouts, D. Bolignano, W. van Biesen
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2014
TLDR
The pharmacology of the most widely used glucose-lowering agents is summarized, whether and how it is altered by a reduced renal function, and the recommendations that can be made for their use in patients with different degrees of CKD are discussed.
Diabetic Pharmacotherapies in Kidney Disease
TLDR
Treatment of diabetes in CKD requires frequent reassessment to meet the patient’s changing drug response and needs, and attention to drug interactions, cautious dose titration, and close glucose monitoring is needed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
PHARMACOKINETIC ASPECTS OF DRUG METABOLISM
  • M. Gibaldi
  • Biology, Medicine
    Annals of the New York Academy of Sciences
  • 1971
The purpose of pharmacokinetics is to study the time course of drug and metabolite concentrations and amounts in various body fluids, tissues, and excreta, and thereby develop suitable mathematical
Disappearance Rate of Tolbutamide in Normal Subjects and in Diabetes Mellitus, Liver Cirrhosis, and Renal Disease
TLDR
In the present studies the disappearance rate of this compound from the blood after its intravenous injection was observed in normal subjects and in patients with diabetes mellitus, liver cirrhosis, and renal disease in relation to changes in arterial blood glucose.
A CLINICAL AND PHARMACOLOGICAL COMPARISON OF CHLORPROPAMIDE AND OTHER SULFONYLUREAS
TLDR
The ultraviolet absorption spectrum of chlorpropamide in the blood seems to be identical with that of the drug in the urine, suggesting that it has undergone no chemical change.
Solid Phase Radioimmunoassay
TLDR
All forms of radioimmunoassay used at present include a procedure to separate free and bound tracer antigen when equilibrium is reached in the incubation mixture, which increases the length and complexity of the assay and introduces a number of possible sources of error.
Solid-Phase Radioimmunoassay in Antibody-Coated Tubes
TLDR
The adsorption of antibody to polymeric surfaces has been used to develop a new method of solid-phase radioimmunoassay that is simple, rapid, inexpensive, and suitable for automation.
Farmacocinet ica e metabolismo in animMi da esperimento e nell 'uomo della N-{4-[fl-(5mctilpirazina-2-corbossiamido)-etil]-b enzensulfonil}N ' cicloesiI-urea (K 4024)
  • Boll. ch in . farm. 111,251 -264
  • 1972
Effet de l 'insuffisance r@nale sur Faction hypoglycdmiante des sulfonylur6es
  • Sehweiz. med. Wsehr. 102, 570--578
  • 1972
...
1
2
3
...